Table 2

Experimental design
Experimental Groups Time-Points (Number of Animals per sex M/F) Key to Abbreviated Terms for Experimental Groups Conditions Describing Experimental Group
Day 45 Day 90 Day 135 Day 180
Control* (5/5) (5/5) (5/5) (5/5) C = Control No-MAP infection; No- probiotics in diet
L-MAP* (5/5) (5/5) (5/5) (5/5) L-MAP = Viable MAP MAP infection; No probiotics in diet
K-MAP (5/5) (5/5) (5/5) (5/5) K-MAP = Non-viable MAP Non-viable MAP antigen; No probiotics in diet
L-NP-51* (5/5) (5/5) (5/5) (5/5) L-NP-51 = Viable Probiotics No-MAP infection; probiotics in diet
L-MAP + L-NP-51* (5/5) (5/5) (5/5) (5/5) L-MAP + L-NP-51= Viable MAP & Probiotics MAP infection; probiotics in diet
K-MAP + L-NP-51* (5/5) (5/5) (5/5) (5/5) K-MAP + L-NP-51 = Non- Viable MAP & Viable Probiotics Non-viable MAP antigen; probiotics in diet
K-NP-51 (5/5) (5/5) (5/5) (5/5) K-NP-51= Non-viable Probiotics Non-viable probiotics in diet
Maltodextrin (5/5) (5/5) (5/5) (5/5) MD= Maltodextrin Filler material in diet
K-MAP + K-NP-51 (5/5) (5/5) (5/5) (5/5) K-MAP + K-NP-51 = Non- viable MAP & Non-viable NP-51 Non-viable MAP antigen; non-viable probiotics in diet
L-MAP + K-NP-51 (5/5) (5/5) (5/5) (5/5) L-MAP + K-NP-51 Viable- MAP antigen; and non- viable probiotics in diet
Total Animals Per Time Point  100

A description of each of the experimental groups, sexes, and treatments are described for one time point, each of the four time points in this study had the same experimental design. Select experimental groups were analyzed for metagenomic, transcriptomic and cytokine analysis based on histopathology results; the selected groups’ are highlighted with '*'.

Karunasena et al.

Karunasena et al. BMC Microbiology 2013 13:8   doi:10.1186/1471-2180-13-8

Open Data